The field of exosome research is growing rapidly, and DHMRI’s exosome discovery platform puts the institute on the field’s leading edge.
Exosomes are circulating extracellular vesicles secreted by almost all cell types. They contain proteins, lipids, antigens and nucleic acids. When first discovered over 30 years ago, extracellular vesicles were considered as membrane debris without real biological significance; however, recent research has shown that exosomes play a critical role in intercellular communication, immune surveillance, tissue repair, blood coagulation and more in both normal biological and aberrant pathological processes.
“Exosomes exist in various body fluids including blood, urine, breast milk, cerebrospinal fluid and feces, and their stable nature and pervasiveness make them ideal biomarkers,” commented Qi Jiang, MD, PhD, associate director of the DHMRI’s In Vitro Sciences Laboratory. “Over the last five years, the DHMRI has developed a platform for exosome biomarker discovery and the ability to profile specific molecules through the use of exosomal biomarker panels.”
DHMRI’s platform provides for the isolation and characterization of exosomes as well as the extraction and sequencing of exosomal RNA and analysis of exosomal proteins. It is enhanced by DHMRI’s genomics, proteomics and metabolomics laboratories and in-house analytical capabilities.
DHMRI is currently conducting projects investigating exosome biomarkers for pre-term birth, poultry disease, brain cancer and traumatic brain injury.
“The expertise we have developed and are continuing to develop in exosomal science provides a unique opportunity for our clients and collaborators to generate new discoveries in disease diagnosis, prevention and treatment,” said DHMRI Chief Operating Officer Steven Colman, PhD. “We invite these researchers to contact us to discuss investigations that we can perform.”
To discuss a project, contact Dr. Colman.
Learn more about the capabilities of the In Vitro Sciences Laboratory.